ZWZhanyu Wang

Zhanyu Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhanyu Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Hongzheng Wang

    School of Pharmacy/Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Shihezi University, Shihezi, P. R. China

    2 shared publications
  • Hui Hui

    State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of -Carcinogenesis and Intervention, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China

    2 shared publications
  • Hui Li

    State Key Laboratory of Natural Medicines Jiangsu Key Laboratory of Carcinogenesis and Intervention China Pharmaceutical University Nanjing People's Republic of China

    2 shared publications
  • Mengyuan Zhu

    Department of oncology, the seventh affiliated hospital of Sun Yat-sen University, Shenzhen, Guangdong, 510080, P.R. China

    2 shared publications
  • Po Hu

    School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Qixia District, Nanjing 210023, China

    2 shared publications
  • Qinglong Guo

    School of Basic Medicine and Clinical Pharmacy China Pharmaceutical University Nanjing Jiangsu China

    2 shared publications

Latest Publications

  • Open Access

    One‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence

    by Yingjie Qing, Hui Li, Yunzi Zhao, Po Hu, Xiangyuan Wang, Xiaoxuan Yu, Mengyuan Zhu, Hongzheng Wang, Zhanyu Wang, Qinglong Guo, et al.

    T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.


  • Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition

    by Xiaoxuan Yu, Hui Li, Mengyuan Zhu, Po Hu, Xiao Liu, Yingjie Qing, Xiangyuan Wang, Hongzheng Wang, Zhanyu Wang, Jingyan Xu, et al.